Microbiota Improving Agent for Selective Pathogen Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pathogenic factor production inhibitors disrupt the balance of resident non-pathogenic bacteria along with pathogenic bacteria, failing to persistently maintain a healthy microbiota balance.
Innovation Solution
A microbiota improving agent containing specific compounds and a base with non-volatile components, including compounds with hydroxy groups, heterocyclic compounds, and ketones, with defined molecular and HLB values, to selectively inhibit pathogenic bacteria while preserving resident non-pathogenic bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a pathogenic factor production inhibitor is used to prevent or reduce the action of pathogenic bacteria, then the pathogenic bacteria action is inhibited, but resident non-pathogenic bacteria are also adversely affected and the inhibitor cannot persistently prevent pathogenic bacteria action
Solution Approach 1:
The patent applies local quality by designing a compound with specific functional groups (oxoacid groups, hydroxy groups, carbonyl groups, imidazole/pyridine skeletons) that create localized chemical environments. These specific structural features enable selective interaction with pathogenic bacteria while sparing non-pathogenic bacteria, achieving localized effectiveness without broad-spectrum damage.
Solution Approach 2:
The patent employs parameter changes by carefully controlling the molecular weight (550 or less) and the mass percentage composition of functional groups (total mass percentage of 45% or more). These parameter specifications optimize the compound's ability to inhibit pathogenic bacteria while maintaining safety for non-pathogenic bacteria, resolving the contradiction between effectiveness and selectivity.
2Reliability
If a pathogenic factor production inhibitor is used to inhibit pathogenic bacteria, then pathogenic bacteria action is reduced, but the microbiota balance cannot be persistently maintained
Solution Approach 1:
The patent implements continuity of useful action by formulating the compound with a base containing non-volatile components. This ensures the active compound remains at the application site for extended periods, providing continuous inhibition of pathogenic bacteria and sustained maintenance of microbiota balance, rather than transient effects that require repeated application.
Solution Approach 2:
The patent uses composite materials by combining the active compound (with specific functional groups and molecular weight) with a base containing non-volatile components. This composite formulation enhances both the stability and persistence of the compound, allowing it to maintain pathogenic bacteria inhibition over time while supporting persistent microbiota balance improvement.
Data Source
AI summary
The present invention aims to provide a microbiota improving agent for improving at least one of mucosal microbiota, skin microbiota, or nail microbiota, the microbiota improving agent exhibiting a high pathogenic bacteria inhibitory effect while maintaining resident non-pathogenic bacteria, thus persistently improving the microbiota balance. The present invention relates to a microbiota improving agent for improving at least one of mucosal microbiota, skin microbiota, or nail microbiota, the microbiota improving agent containing: a substance (X); and a base (Y) containing a non-volatile component, the substance (X) including at least one selected from the group consisting of a compound (X1) having two or more hydroxy groups contained in at least one oxoacid group and a salt of the compound (X1), a compound (X2) having one hydroxy group contained in an oxoacid group and a salt of the compound (X2), a heterocyclic compound (X3) having no oxoacid group and a salt of the compound (X3), and a ketone (X4) having no oxoacid group. In the compound (X1), a total mass percentage of the at least one oxoacid group, a hydroxy group not contained in the oxoacid group, a carbonyl group not contained in the oxoacid group, carbon atoms contained in an imidazole skeleton and a pyridine skeleton, and nitrogen atoms contained in the imidazole skeleton and the pyridine skeleton is 45% by mass or more based on a molecular weight of the compound (X1). The compound (X2) has an atom having an unshared electron pair, the atom excluding atoms contained in the oxoacid group and atoms contained in an amino group not constituting an imidazole skeleton and in an amino group not constituting a pyridine skeleton. In the compound (X2), a total mass percentage of the oxoacid group, a hydroxy group not contained in the oxoacid group, a carbonyl group not contained in the oxoacid group, carbon atoms contained in an imidazole skeleton and a pyridine skeleton, and nitrogen atoms contained in the imidazole skeleton and the pyridine skeleton is 55% by mass or more based on a molecular weight of the compound (X2). The heterocyclic compound (X3) has an imidazole skeleton or a pyridine skeleton and at least one of a hydroxy group or a carbonyl group, or has two or more skeletons selected from the group consisting of an imidazole skeleton and a pyridine skeleton. The ketone (X4) has a linear β-diketone structure. The substance (X) has a molecular weight of 550 or less. The non-volatile component has an HLB value of 7 or more. The microbiota improving agent satisfies the following conditions (i) and (ii): (i) the microbiota improving agent has a worked penetration of 100 to 400 as measured in accordance with JIS K 2220; and (ii) the microbiota improving agent has a viscosity at 37° C. of 1 to 4,000 Pa·s as measured with a cone-and-plate rheometer.